August 2026 in “Prostaglandins & Other Lipid Mediators” This review suggests that imbalance in prostaglandin levels may contribute to androgenetic alopecia, highlighting prostaglandins as potential biomarkers and therapeutic targets for the condition.
9 citations
,
December 2020 in “Dermatologic Therapy” This review found that oral and topical phosphodiesterase inhibitors and topical prostaglandin analogues are safe and effective treatments for various skin diseases, including psoriasis, atopic dermatitis, vitiligo, and alopecia.
January 2024 in “Frontiers in endocrinology” This study found that women treated with GnRHa for central precocious puberty had a higher prevalence of polycystic ovary syndrome in adulthood compared to those with isolated premature thelarche.
1 citations
,
September 2023 in “JCEM case reports” This case series observed the efficacy of GnRH analogues in diagnosing and treating various forms of ovarian hyperandrogenism, illustrating their role in symptom management without surgery, particularly for benign conditions and refractory androgen excess.
January 2026 in “International Journal of Women s Health” This study found that a nomogram prediction model based on clinical characteristics, bone metabolism, and ovarian function can effectively predict the treatment response to long-acting GnRHa in girls with idiopathic central precocious puberty.
